Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a fourth drug tip the scales against an aggressive leukemia?

NCT ID NCT07726576

Not yet recruiting ⭐️ CURE ⭐️ Sponsor: University Hospital, Bordeaux Source: ClinicalTrials.gov ↗

First seen Jul 24, 2026 · Last updated Jul 24, 2026

Summary

This trial is testing whether adding venetoclax to standard intensive chemotherapy plus midostaurin can improve outcomes for adults with a type of acute myeloid leukemia that has a FLT3 mutation. The study enrolls people aged 18 to 70 with newly diagnosed disease who are healthy enough for strong chemotherapy. Researchers are looking for higher rates of complete remission without detectable cancer cells, and longer survival.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
venetoclax added to standard chemotherapy (daunorubicin and cytarabine) plus midostaurin
What this could lead to
If successful, this four-drug combination could become a new standard treatment that improves remission and survival for people with this aggressive leukemia.
What could go wrong
This is an early-phase trial with only 41 participants, so the added benefit and safety of venetoclax in this intensive regimen are not yet known. Adding more drugs may increase side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LEUKEMIA, MYELOID, ACUTE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LEUKEMIA, MYELOID, ACUTE

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • CH de la Côte Basque

    Bayonne, 64100, France

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • CHU de Bordeaux - Hôpital haut-Lévêque

    Pessac, 33600, France

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • CHU de Toulouse

    Toulouse, 31059, France

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.